The utility of recombinant factor VIIa as a last resort in trauma

World Journal of Emergency Surgery

Volumn 7, Issue , 2012, Pages

  Mamtani, Rishi ^a   Nascimento, Bartolomeu ^a   Rizoli, Sandro ^b   Pinto, Ruxandra ^a   Lin, Yulia ^a   Tien, Homer ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85028894935     PISSN: None     EISSN: 17497922     Source Type: Journal    
DOI: 10.1186/1749-7922-7-S1-S7     Document Type: Conference Paper

References (31)

1. Hedner U: Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006, 124(4):747-57, Epub 2006 May 12. Review
2. Parameswaran R, Shapiro AD, Gill JC, et al: Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005, 11(2):100-6
3. Hedner U: Recombinat factor VIIa: its background, development and clinical use. Curr Opin Hematol 2007, 14:225-9, doi: 10.1097/MOH. 0b013e3280dce57b
4. Kenet G, Walden R, Eldad A, et al: Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999, 354(9193):1879
5. Martinowitz U, Kenet G, Lubetski A, et al: Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth 2002, 49(10):S15-20
6. Mohr AM, Holcomb JB, Dutton RP, et al: Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma. Crit Care 2005, 9(Suppl 5):S37-42, Epub 2005 Oct 7
7. Barletta JF, Ahrens CL, Tyburski JG, et al: A review of recombinant factor VII for refractory bleeding in nonhemophilic trauma patients. J Trauma 2005, 58(3):646-51
8. Boffard KD, Riou B, Warren B, et al: NovoSeven Trauma Study Group. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebocontrolled, double-blind clinical trials. J Trauma 2005, 59(1):8-15, discussion 15-8
9. Hauser CJ, Boffard K, Dutton R, et al: CONTROL Study Group. Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. J Trauma 2010, 69(3):489-500
10. Dutton RP, Parr M, Tortella BJ, et al: Recombinant Activated Factor VII Safety in Trauma Patients: Results from the CONTROL Trial. J Trauma 2011, 71(1):12-19
11. Lin Y, Stanworth SJ, Birchall J, et al: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2011, 2: CD005011
12. Levi M, Levy JH, Andersen HF, et al: Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010, 363(19):1791-800, Erratum in: N Engl J Med. 2011 Nov 17;365(20):1944
13. Wade CE, Eastridge BJ, Jones JA, et al: Use of recombinant factor VIIa in US military casualties for a five-year period. J Trauma 2010, 69(2):353-9
14. Woodruff SI, Dougherty AL, Dye JL, et al: Use of recombinant factor VIIA for control of combat-related haemorrhage. Emerg Med J 2010, 27(2):121-4
15. Rossaint R, Bouillon B, Cerny V, et al: Management of bleeding following major trauma: an updated European guideline. Crit Care 2010, 14(2):R52
16. Vincent JL, Rossaint R, Riou B, et al: Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding-a European perspective. Crit Care 2006, 10(4):R120
17. Meng ZH, Wolberg AS, Monroe DM 3rd, et al: The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003, 55(5):886-91
18. Lesperance RN, Lehmann RK, Harold DM, et al: Recombinant Factor VII is Effective at Reversing Coagulopathy in a Lactic Acidosis Model. J Trauma 2011, [Epub ahead of print]
19. Ho KM, Litton E: Cost-effectiveness of using recombinant activated factor VII as an off-label rescue treatment for critical bleeding requiring massive transfusion. Transfusion 2011, doi: 10.1111/j.1537-2995.2011.03505.x. [Epub ahead of print]
20. Nascimento B, Lin Y, Callum J, et al: Recombinant factor VIIa is associated with an improved 24-hour survival without an improvement in inpatient survival in massively transfused civilian trauma patients. Clinics (Sao Paulo) 2011, 66(1):101-6
21. Rizoli SB, Nascimento B Jr, Osman F, et al: Recombinant activated coagulation factor VII and bleeding trauma patients. J Trauma 2006, 61(6):1419-25
22. David: Recombinant Activated Human Factor VII (NovoSeven). [http:// www.canadianmedicine4all.com/recombinant-activated-human-factor-viinovoseven. html]
23. Stein DM, Dutton RP, Hess JR, et al: Low-dose recombinant factor VIIa for trauma patients with coagulopathy. Injury 2008, 39(9):1054-61
24. Karkouti K, Beattie WS, Arellano R, et al: Comprehensive Canadian Review of the Off-Label Use of Recombinant Activated Factor VII in Cardiac Surgery. Circulation 2008, 118(4):331-8, Epub 2008 Jul 7
25. James I, John M: Australia and New Zealand Haemostasis Registry. Monsah University, Australia; 2010
26. Hess JR, Brohi K, Dutton RP, et al: The Coagulopathy of Trauma: A Review of Mechanisms. J Trauma 2008, 65(4):748-54, Review
27. Knudson MM, Cohen MJ, Reidy R, et al: Trauma, Transfusions, and Use of Recombinant Factor VIIa: A Multicenter Case Registry Report of 380 patients from the Western Trauma Association. J Am Coll Surg 2011, 212(1):87-95, Epub 2010 Nov 5
28. CRASH-2 Trial Collaborators: Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) a randomized, placebo-controlled trial. Lancet 2010, 376(9734):23-32, Epub 2010 Jun 14
29. Guerriero C, Cairns J, Perel P, et al: Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial. PLoS One 2011, 6(5):e18987
30. Charoencholvanich K, Siriwattanasakul P: Tranexamic Acid Reduces Blood Loss and Blood Transfusion after TKA: A Prospective Randomized Controlled Trial. Clin Orthop Relat Res 2011, Epub ahead of print
31. Sepah YJ, Umer M, Ahmad T, et al: Use of Tranexamic acid is a cost effective method in preventing blood loss during and after total knee replacement. J Orthop Surg Res 2011, 6(1):22